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The thienopyridines ticlopidine and clopidogrel can cause neutropenia and 
agranulocytosis. The aim of the current investigations was to compare cytotoxicity of 
these compounds for human neutrophil granulocytes with the toxicity for 
lymphocytes and to characterize underlying mechanisms. For granulocytes, 
clopidogrel, ticlopidine and clopidogrel carboxylate were concentration-dependently 
toxic starting at 10µM. Cytotoxicity could be prevented by the myeloperoxidase 
inhibitor rutin, but not by the cytochrome P450 blocker ketoconazole. For 
lymphocytes, clopidogrel and ticlopidine were concentration-dependently toxic 
starting at 10µM. In contrast to granulocytes, cytotoxicity for lymphocytes could not 
be blocked by rutin or ketoconazole. Clopidogrel carboxylate was toxic for 
lymphocytes starting at 10µM, but without a clear concentration dependency. 
Cytotoxicity for lymphocytes could not be prevented by rutin or ketoconazole. 
Granulocytes metabolized clopidogrel, ticlopidine and clopidogrel carboxylate and 
the metabolism was inhibited by rutin, but not by ketoconazole. Metabolism of these 
compounds by lymphocytes was much slower and could not be inhibited by 
ketoconazole or rutin. In granulocytes, all compounds investigated decreased the 
mitochondrial membrane potential, were associated with cellular accumulation of 
ROS, mitochondrial loss of cytochrome c and induction of apoptosis. In conclusion, 
clopidogrel, ticlopidine and clopidogrel carboxylate are toxic for both granulocytes 
and lymphocytes. For granulocytes, cytotoxicity of these compounds is significantly 
increased after metabolization by myeloperoxidase. The current studies suggest a 
mitochondrial mechanism for cytotoxicity for both parent compounds and 
myeloperoxidase-associated metabolites. 
Key words: clopidogrel, ticlopidine, clopidogrel carboxylate, myelotoxicity, 
granulocytes, lymphocytes. 
  Page 50  
!"# $%%&'()*+),-./
 
• MPO: myeloperoxidase 
• CYP: cytochrome P450 
• IMDM: Iscove’s modified Dulbecco’s medium 
• PBS: phosphate-buffered saline 
• FBS: fetal bovine serum 
• PI: propidium iodide 
• TMRE: tetramethylrhodamine ethyl ester 
• DCFH-DA: dichlorodihydrofluorescein-diacetate 
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The thienopyridines clopidogrel and ticlopidine block the ADP (P2Y12) receptors on 
blood platelets and thereby efficiently inhibit platelet aggregation 1-3. 
Thienopyridines are used widely in patients with cardiovascular diseases, in 
particular in patients with acute coronary syndrome 4-6, but also in patients with 
cerebrovascular or peripheral artery disease 7-9. 
The most important adverse reaction of these drugs is bleeding 10,11. In patients 
treated with the combination aspirin and clopidogrel, non-fatal bleeding episodes 
occur in approximately 7% of the patients per year and fatal bleeding in 0.6% 10. 
Hematotoxicity is less frequent, occurring in up to 3% of the patients treated with 
ticlopidine 9,12 and approximately 1% of the patients treated with clopidogrel 13. 
Important hematological adverse effects associated with these drugs include 
neutropenia and agranulocytosis 14-18, thrombocytopenia 13,19,20, aplastic anemia 21,22, 
thrombotic thrombocytopenic purpura 23,24, and the hemolytic uremic syndrome 25. 
In patients with neutropenia or agranulocytosis associated with thienopyridines, 
bone marrow investigations have shown impaired myelopoiesis 26,27, compatible with 
a direct toxic effect on the bone marrow. The association of the thienopyridines with 
aplastic anemia 21,22 also suggests a direct toxicity on the bone marrow. The precise 
mechanism associated with myelotoxicity of these drugs is so far not entirely clear, 
however. Liu and Uetrecht have demonstrated that ticlopidine can be oxidized by 
myeloperoxidase (MPO) in neutrophil granulocytes to a reactive thiophene-S-
chloride derivative 28, which may be associated with bone marrow toxicity. In line 
with this study, we have shown recently that metabolites formed by MPO in 
neutrophil granulocytes of ticlopidine, clopidogrel or the clopidogrel metabolite 
clopidogrel carboxylate are toxic for cultured human myelopoietic progenitor cells 29. 
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Another possible explanation for hemotoxicity of these compounds could be by 
cytochrome P450 (CYP)-associated production of toxic metabolites by cells in the 
bone marrow, circulating blood cells and/or hepatocytes. Both clopidogrel and 
ticlopidine are prodrugs needing activation to be active. Activation of clopidogrel 
and ticlopidine is achieved by oxidation of the thiophene ring and hydrolytic ring 
opening of the thioester formed 3,30. The free mercapto-group can not only covalently 
bind a cysteine residue of the P2Y12-receptor on platelets 
2, but possibly also other 
proteins or peptides with free mercapto groups such as for instance glutathione 31. 
The fact that both ticlopidine and clopidogrel are mechanism-based inhibitors of 
CYP2B6 and CYP2C19 32,33 supports this hypothesis. 
While we could demonstrate that metabolites formed by MPO or CYP3A4 from 
clopidogrel or ticlopidine are toxic for human myelopoietic progenitor cells 29, it is 
currently unclear whether also mature blood cells can be affected and which 
mechanisms are responsible for myelotoxicity of these compounds on a cellular level. 
We therefore isolated and enzymatically characterized the most abundant bone 
marrow cells from peripheral blood, neutrophil granulocytes and lymphocytes, and 
studied metabolism and toxicity of ticlopidine, clopidogrel and clopidogrel 
carboxylate by and for these cells. 
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Clopidogrel hydrogen sulphate was extracted from commercially available tablets 
(brand name Plavix®) and clopidogrel carboxylate was obtained by alkaline 
hydrolysis of clopidogrel. These procedures were carried out by ReseaChem Life 
Sciences (Burgdorf, Switzerland). Both substances were >99% pure by NMR analysis. 
Ticlopidine was obtained from Sigma-Aldrich (Buchs, Switzerland). Cell culture 
plates were purchased from BD Biosciences (Franklin Lakes, NJ, USA). All other 
chemicals and culture media used were purchased from Sigma (Buchs, Switzerland) 
or GIBCO (Lucerne, Switzerland). 
!"#"3 4'**,*)-'+,%-.,5'**,56*&6('7,
Normal donor buffy coats were purchased from the local blood donation center, 
Basel (Switzerland). Blood cells were isolated from the buffy coat by a modification 
of the method described by Klebanoff et al. 34. Briefly, the buffy coat was diluted 1:2 
with Iscove’s modified Dulbecco’s medium (IMDM) and mixed with 4% dextran 
(MW 500’000 kD) in 0.9% NaCl (Sigma, Buchs, Switzerland) to allow erythrocytes to 
settle for 30 min. The supernatant layer was washed with phosphate-buffered saline 
(PBS), underlayed with 20 ml of cold Ficoll-Paque (GE Healthcare, Switzerland) and 
centrifuged at 500 g for 25 min. The supernatant containing PBMCs and the pellet 
containing neutrophil granulocytes were washed with phosphate-buffered saline 
(PBS) and resuspended separately with 10 ml of ice-cold 0.2% NaCl for 1 min to 
induce hypotonic lysis of contaminating erythrocytes. Isotonicity was restored by 
adding an equal volume of 1.6% NaCl. The suspensions were centrifuged at 350 g for 
5 min and the pellets were washed twice with PBS. The pellets were then 
resuspended in IMDM containing 10% fetal bovine serum (FBS). Cells were counted 
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and the cell viability was assessed using trypan blue analysis. For the experiments, 
500,000 freshly isolated lymphocytes or neutrophils in 1 mL IMDM containing 10% 
FBS per well were seeded in 24-well plates. Stock solutions of test compounds 
(clopidogrel, clopidogrel carboxylic acid and ticlopidine) were prepared in DMSO. 
The test compounds were added at a concentration of 1 to 100µM in presence or 
absence of CYP3A4 inhibitor ketoconazole (1µM) 31 or the MPO inhibitor rutin 
(20µM) 35. The DMSO concentration was 0.1% in all incubations, including control 
incubations. This DMSO concentration is not cytotoxic 36. Staurosporine (STS, final 
concentration 1µM) was used as a positive control for cytotoxicity. 
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Quantitative real time PCR was performed to check for the presence of CYPs 
potentially responsible for metabolism of thienopyridines. Neutrophils or 
lymphocytes were lysed with 350µl of RLT buffer (Qiagen, Hombrechtikon, 
Switzerland) and the lysate was transferred to Qiashredder columns and spinned for 
2 min at 13,000 rpm. From the eluate, total RNA was extracted according to the 
manufacturer’s protocol (Qiagen RNeasy Mini Extraction kit). cDNA was reverse 
transcribed from the isolated RNA using the Qiagen Omniscript system. For 
quantitative RT-PCR 10ng cDNA was used. Forward and reverse primers for all 
CYPs tested, MPO and GAPDH (Table 1 for primers) were purchased from 
Microsynth (Balgach, Switzerland). RT-PCR was performed on an ABI PRISM 7700 
sequence detector (PE Biosystems, Rotkreuz, Switzerland). Quantification of mRNA 
expression levels was performed using the SYBR-Green fluorescence method (Roche, 
Basel, Switzerland). 
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Neutrophils or lymphocytes were lysed on ice for 15 min with 200µl NET lysis buffer 
(50mM NaCl, 5mM EDTA, 50mM Tris-HCl pH 8.0, 1% NP-40 and a protease 
inhibitor tablet from Roche [Basel, Switzerland]). The samples were centrifuged for 
10min at 4°C at 11,000 g and the supernatant was collected. The protein 
concentration was determined using the Pierce BCA protein assay kit (Darmstadt, 
Germany). Proteins (20µg) were separated by electrophoresis on a denaturating SDS 
polyacrylamide gel (4%) in the presence of molecular weight standards. After 
separation, proteins were transferred onto a nitrocellulose membrane 
(BioradTransBlot, Hercules, CA). The membranes were blocked with PBS-Tween 20 
containing 5% milk solution (w/v) for 1h at room temperature and washed twice 
with PBS-Tween 20. The blocked membranes were incubated overnight at 4°C with 
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5% milk solution containing primary antibodies against MPO (Cell Signaling 
Technology, Allschwil, Switzerland), CYP3A4, CYP2C19 (Epitomics, Danvers, USA), 
CYP2B6, CYP1A2 (Abcam, Cambridge, UK) or CYP2C9 (BD bioscience, Allschwil, 
Switzerland). All of the antibodies mentioned were diluted according to the 
manufacturer’s instructions. Horseradish peroxidase-conjugated anti-rabbit or anti-
goat antibodies (Jackson laboratories Inc, Suffolk, UK) were used in combination 
with a chemiluminescent substrate (ECL, Amersham, UK) for protein visualization. 
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The cytotoxicity assay was performed to determine the percentage of dead (necrotic 
or late apoptotic) cells in the incubations. Propidium iodide (PI) is a red fluorescent 
dye used to distinguish living cells having intact cell membranes (exclude PI) from 
dead cells having disrupted cell membranes (permeable to PI). The cells were treated 
for 24h with the test compounds in the presence or absence of the CYP3A4 inhibitor 
ketoconazole (1µM) or the MPO inhibitor rutin (20µM). After the incubation, cells 
were centrifuged at 350 g for 5min and washed with PBS before PI staining (final 
concentration 5µg/ml). Flow cytometry analysis was carried out with a FACS 
CaliburTM using CellQuest Pro software (BD Bioscience, Allschwil, Switzerland). 
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Neutrophils or lymphocytes (4.5 x 106/ml in 24-well plates) were incubated with 
clopidogrel, ticlopidine or clopidogrel carboxylate (10 or 100µM) at 37°C for different 
periods of time (0, 6, 12 and 24 h) in the presence or absence of the CYP3A4 inhibitor 
ketoconazole (1µM) or the MPO inhibitor rutin (20µM). Reactions were stopped by 
the addition of 300µl of methanol and the precipitated proteins were removed by 
centrifugation at 3000 g for 30min. The samples were analyzed by LC-MS as 
described previously 29. 
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To detect the changes in mitochondrial membrane potential, cells were exposed to 
tetramethylrhodamine ethyl ester (TMRE). Cells were incubated with drugs in 
presence or absence of ketoconazole (1µM) or rutin (20µM) for 24h. After the 
incubation, cells were washed twice with PBS and incubated with 100nM TMRE in 
PBS for 30min at room temperature. The fluorescence signal of the cationic dye was 
monitored by flow cytometry using a FACS CaliburTM equipped with CellQuest Pro 
software (BD Bioscience, Allschwil, Switzerland). 
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Cellular ROS generation was measured using the 2’, 7’-dichlorodihydrofluorescein-
diacetate (DCFH-DA) assay 37. Cells (5 x 105 cells /ml) were co-incubated with drugs 
and 25µM DCFH-DA in the presence or absence of ketoconazole (1µM) or rutin 
(20µM). After an incubation of 24h, fluorescence was measured at an excitation 
wavelength of 485 nm and an emission wavelength of 535 nm using a Tecan Infinite 
pro 200 microplate reader (Tecan, Männedorf, Switzerland). 
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The cytochrome c content in the cells was analyzed using the method escribed by 
Waterhouse et al. 34,38 with some modifications. Briefly, after 24 h of drug treatment, 
the cells were washed with PBS and subsequently permeabilized on ice with 100µl of 
digitonin 50 µg/ml in PBS containing 100mM KCl for 10min. The cells were then 
fixed with paraformaldehyde (4% in PBS) at room temperature. After 30 min, the 
cells were washed twice with PBS and incubated for 1h in blocking buffer (PBS 
containing 3% BSA and 0.05% saponin). Afterwards, cells were incubated at 4°C 
overnight with a monoclonal anti-cytochrome c antibody (BD Pharmingen, 
Allschwil, Switzerland), which was diluted 1:500 in blocking buffer. Finally, cells 
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were washed twice with PBS and incubated with an Alexa Fluor®-labeled secondary 
antibody (Invitrogen, Basel, Switzerland) diluted 1:500 in blocking buffer for 1 h at 
room temperature and analyzed by flow cytometry. 
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Caspase 9 activity was determined in both cell lines using the Caspase-Glo® 9 assay 
according to the protocol of the manufacturer (Promega, Dübendorf, Switzerland). 
Cells (105 cells/well) were seeded in a white walled 96-well plate and treated with 
the drugs mentioned above in presence or absence of ketoconazole (1µM) or rutin 
(20µM). After 24h of incubation, an equal volume of assay buffer was added to the 
cells. The plates were then shaken at 400 rpm for 30sec and again incubated for 1h. 
Luminescence was measured using the Tecan Infinite pro 200 microplate reader. 
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Data are presented as mean ± SD of at least four independent experiments, except 
where indicated. Statistical analyses were performed using GraphPad Prism 5 
(GraphPad Software, La Jolla, CA, USA). Differences between groups (e.g. 
incubations containing drugs vs. control incubations) were tested by one-way 
ANOVA followed by Bonferroni’s post hoc test to localize significant results in the 
ANOVA. Differences between many groups at two levels were compared using two-
way analysis of variance (ANOVA) followed by the protected Bonferroni’s post hoc 
test to localize significant results obtained in the ANOVA. A p-value <0.05 was 
considered as statistically significant. 
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mRNA expression levels of multiple CYPs and MPO were analyzed in human 
neutrophils and lymphocytes. As shown in Table 2, the mRNA expression of CYPs 
was generally lower in neutrophils compared to lymphocytes. In both cell types, the 
CYP with the highest mRNA expression was CYP1B1, followed by CYP5A1 and 
CYP26B1. None of these CYPs has been associated with the activation of clopidogrel 
or ticlopidine. The CYPs associated with activation of ticlopidine and/or clopidogrel 
(CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4) revealed only a low mRNA 
expression in both lymphocytes and neutrophil granulocytes. As expected, the 
mRNA expression of MPO was high in neutrophils and low in lymphocytes. The 
protein expression data were consistent with mRNA expression (Figure 1). 
Neutrophils did not express CYPs associated with the activation of clopidogrel or 
ticlopidine but had a high expression of MPO. In comparison, lymphocytes 
expressed neither CYPs nor MPO. 
 
Figure 1 Protein expression of MPO and CYPs in human neutrophils and lymphocytes. The Western 
blot was carried out as described in Methods. Positive controls used were human microsomes (lane 1) 
for cytochrome P450 enzyme expression and HL-60 cells for myeloperoxidase expression (lane 4). 
Lanes 2 and 3 contain human neutrophil granulocytes and lymphocytes, respectively. 
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Gene Lymphocytes (Ct) Neutrophil 
granulocytes (Ct) 
GADPH 18.9 ± 0.3 17.4 ± 0.3 
MPO 26.8 ± 0.3 21.7 ± 0.4 
CYP1A1 31.7 ± 0.1 33.1 ± 2.4 
CYP1A2 30.3 ± 0.1 32.5 ± 1.2 
CYP1B1 20.3 ± 0.7 20.8 ± 1.6 
CYP2A6 31.7 ± 0.1 31.8 ± 0.1 
CYP2B6 31.6 ± 0.9 30.6 ± 1.0 
CYP2C8 29.4 ± 0.2 30.1 ± 0.4 
CYP2C9 30.9 ± 0.1 N.D 
CYP2C19 N.D 34.4 ± 1.0 
CYP2D6 31.3 ± 0.1 33.6 ± 0.3 
CYP2E1 29.7 ± 0.1 33.4 ± 1.2 
CYP3A4 30.3 ± 0.1 35.0 ± 0.1 
CYP3A5 30.1 ± 0.1 28.7 ± 0.7 
CYP5A1 26.2 ± 0.1 23.9 ± 0.3 
CYP26A1 30.9 ± 0.1 31.4 ± 2.0 
CYP26B1 28.5 ± 0.4 24.6 ± 0.2 
CYP26C1 N.D N.D 
 
 
Table 2 CYP mRNA expression in human lymphocytes and neutrophil granulocytes. Three 
independent experiments were performed as described in Methods. Data are expressed as the Ct 
value. N.D: not detectable (Ct value not determinable). 
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Cytotoxicity was assessed using PI staining and subsequent FACS analysis (Figure 
2). For neutrophils exposed for 24 h, clopidogrel, ticlopidine or clopidogrel 
carboxylate showed a concentration-dependent toxicity starting at 10µM. This 
toxicity could at least partially be prevented by 20µM rutin, a MPO inhibitor 35, but 
not significantly by the CYP inhibitor ketoconazole 31. Considering lymphocytes, 
clopidogrel and ticlopidine were cytotoxic starting at 10µM with a clear 
concentration-dependency, but this cytotoxicity could not be prevented by rutin or 
ketoconazole. Clopidogrel carboxylate was also cytotoxic for lymphocytes, starting at 
10µM. This cytotoxicity was not clearly concentration-dependent, was less 
accentuated than the cytotoxicity associated with clopidogrel or ticlopidine and 
could not be prevented by rutin or ketoconazole. 
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Figure 2 Cytotoxicity of clopidogrel, ticlopidine and clopidogrel carboxylate for neutrophil 
granulocytes and lymphocytes. Both neutrophil granulocytes and lymphocytes were exposed for 24h 
to the compounds mentioned above at the concentrations indicated in the Figure labels. Some 
incubations contained also 1µM ketoconazole (CYP3A4 inhibitor) or 20µM rutin (MPO inhibitor) as 
indicated in the figure labels. Cytotoxicity was measured using propidium iodine staining. DMSO-
treated cells (0.1%) were used as control incubations (Ctrl) and cells treated with 1µM staurosporine as 
a positive control. The results were normalized to control incubations and are expressed as the means 
+ SD of four independent experiments. (a) p<0.05 incubations containing drugs without pretreatment 
versus respective control incubations; (b) p<0.05 incubations containing drugs and rutin or 
ketoconazole versus corresponding incubations containing drugs only. STS: staurosporine, Clp: 
clopidogrel, Tcp: ticlopidine, CCA: clopidogrel carboxylate. 
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The metabolism of the compounds mentioned above by freshly isolated human 
neutrophils or lymphocytes were studied using LC-MS/MS. After 24 h of incubation 
with neutrophils, the compounds were degraded by 20 to 60%, depending on the 
compound and on the initial concentration (Fig. 3). The metabolism of the 
compounds investigated was not significantly influenced by ketoconazole, which is 
compatible with the observation that neutrophils have no protein expression of 
CYP3A4 (Fig. 2). In the presence of rutin, the metabolism of the compounds was 
prevented almost completely, indicating that MPO present in neutrophils is the most 
important enzyme for metabolism of the thienopyridines investigated. In contrast, 
the incubations with lymphocytes showed no (clopidogrel carboxylate) or only a 
minor metabolization of the compounds tested (<20% for clopidogrel and 
ticlopidine), which could not be inhibited by ketoconazole or rutin (Fig. 4). This 
finding is compatible with the observation that lymphocytes have no protein 
expression of CYP3A4 and MPO (Fig. 2). 
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Figure 3 Metabolism of clopidogrel, ticlopidine and clopidogrel carboxylate by human neutrophil 
granulocytes. Clopidogrel 10µM (A), clopidogrel 100µM (B), ticlopidine10µM (C), ticlopidine100µM 
(D), clopidogrel carboxylate 10 µM (E) or clopidogrel carboxylate 100µM (F) were incubated with 
neutrophil granulocytes as described in Methods. Some incubations contained also the 
myeloperoxidase inhibitor rutin (20µM) or the CYP3A4 inhibitor ketoconazole (1µM) as indicated in 
the Figure labels. Data are expressed as the percentage of drug remaining during 24 h of incubation. 
The results are the means + SD of three independent determinations. (a) p<0.05 versus respective 
incubations at time 0 min; (b) p<0.05 incubations containing drug with 20µM rutin versus respective 
incubations containing drug only. 
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Figure 4 Metabolism of clopidogrel, ticlopidine and clopidogrel carboxylate by human lymphocytes. 
Clopidogrel 10µM (A), clopidogrel 100µM (B), ticlopidine10µM (C), ticlopidine100µM (D), clopidogrel 
carboxylate 10 µM (E) or clopidogrel carboxylate 100µM (F) were incubated with lymphocytes for 24 
h. Some incubations contained also rutin (20µM) or ketoconazole (1µM) as indicated in the Figure. 
Data are expressed as the percentage of drug remaining during 24 h of incubation. The results are the 
means + SD of three independent determinations. (a) p<0.05 versus respective incubations at time 0 
min; (b) p<0.05 incubations containing drug with 20µM rutin versus respective incubations containing 
drug only. 
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The mitochondrial membrane potential (!m) is maintained mainly by the proton 
gradient generated by the activity of complexes of the electron transport chain. The 
mitochondrial membrane potential is therefore a marker of mitochondrial function 
36,37. We investigated the changes in mitochondrial !m with the dye TMRE, which 
accumulates in mitochondria depending on !m (Fig. 5). In neutrophils, all 
compounds tested decreased !m in a concentration-dependent fashion, but without 
reaching significance for 10µM. This effect could almost completely be prevented by 
rutin, but not by ketoconazole. In contrast, in lymphocytes, only clopidogrel and 
ticlopidine were associated with a concentration-dependent decrease of !m, whereas 
clopidogrel carboxylate did not significantly affect !m. In contrast to neutrophils, 
neither rutin nor ketoconazole could prevent the toxicity of clopidogrel or ticlopidine 
on lymphocytes. 
!"!"! $%%&'() *%) '+*,-.*/0&+1) (-'+*,-.-2&) *0) '+*,-.*/0&+) '304*56+3(&) *2) (7&)
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Mitochondrial dysfunction can be associated with increased production of ROS 37. As 
shown in Figure 6, ROS production by neutrophils increased dose-dependently and 
significantly in the presence of all compounds investigated, starting at 10µM. This 
increase could be prevented almost completely by the addition of rutin, whereas 
ketoconazole was clearly less effective. Concerning lymphocytes, there was a 
significant increase of cellular ROS levels only at high concentrations (100µM) of 
clopidogrel and ticlopidine and neither rutin nor ketoconazole could prevent this 
increase. Clopidogrel carboxylate had no effect on cellular ROS levels in 
lymphocytes. 
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Figure 5 Effect of clopidogrel, ticlopidine and clopidogrel carboxylate on mitochondrial membrane 
potential in neutrophil granulocytes and lymphocytes. Cells were exposed for 24h to different 
concentrations of the compounds indicated above as indicated in the Figure labels. Some incubations 
contained ketoconazole (1µM) or rutin (20µM) as indicated in Figure labels. TMRE was used to 
determine the mitochondrial membrane potential (!m) as described in Methods. The results were 
normalized to control incubations containing 0.1% DMSO. Incubations containing 1µM staurosporine 
were used as a positive control. Results are presented as the mean + SD of four independent 
experiments. (a) p<0.05 incubations containing drugs alone versus respective control incubations 
(Ctrl); (b) p<0.05 Incubations containing drugs and rutin or ketoconazole versus corresponding 
incubations containing drugs only. STS: staurosporine, Clp: clopidogrel, Tcp: ticlopidine, CCA: 
clopidogrel carboxylate. 
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Figure 6 ROS formation by neutrophils granulocytes and lymphocytes. Cells were treated for 24h with 
clopidogrel, ticlopidine or clopidogrel carboxylate at the concentrations indicated in the Figure labels. 
Some incubations contained also 1µM ketoconazole or 20µM rutin as indicated in the Figure labels. 
Cellular levels of ROS were measured using 2’, 7’-dichlorodihydrofluorescein-diacetate (DCFH-DA) 
as described in Methods. Cells treated with 0.1% DMSO were used as negative (Ctrl) and cells treated 
with 1µM staurosporine as a positive control. The results were normalized to control incubations 
(Ctrl) and are expressed as mean + SD of four independent experiments. (a) p<0.05 incubations 
containing drugs alone versus respective control incubations (Ctrl); (b) p<0.05 incubations containing 
drugs and rutin or ketoconazole versus corresponding incubations containing drugs only. STS: 
staurosporine, Clp: clopidogrel, Tcp: ticlopidine, CCA: clopidogrel carboxylate. 
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Increased mitochondrial production of ROS can lead to mitochondrial membrane 
permeabilization and release of mitochondrial proteins (e.g. cytochrome c) into the 
cytoplasm. We therefore investigated the effect of the thienopyridines on the 
mitochondrial cytochrome c content (Figure 7). In neutrophils incubated for 24 h 
with clopidogrel, ticlopidine or clopidogrel carboxylate, the mitochondrial 
cytochrome c content showed a concentration-dependent decrease. This decrease 
could be prevented completely by rutin, but not by ketoconazole. In lymphocytes, 
only clopidogrel and ticlopidine were associated with a concentration-dependent 
decrease in the mitochondrial cytochrome c content, whereas clopidogrel carboxylate 
was without a significant effect. Rutin did not prevent the drop in mitochondrial 
cytochrome c for clopidogrel or ticlopidine and also ketoconazole was without a 
significant preventive effect. 
!"!"9 :'(-;3(-*2) *%) '3<,3<&) =) 46) '+*,-.*/0&+1) (-'+*,-.-2&) *0) '+*,-.*/0&+)
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Release of cytochrome c from mitochondria into the cytoplasm can activate the 
apoptosome (apaf-1), which cleaves pro-caspase-9 to caspase-9 and eventually 
triggers apoptosis. We therefore determined the activity of caspase-9 as a surrogate 
of apoptosis (Figure 8). In neutrophils, all compounds investigated were associated 
with a concentration-dependent activation of caspase-9 starting at 10µM. The 
activation could at least partially be prevented by rutin, whereas ketoconazole was 
not associated with a significant prevention of caspase-9 activation. In lymphocytes, 
only the higher concentration (100µM) of clopidogrel and ticlopidine induced 
activation of caspase-9, whereas clopidogrel carboxylate had no effect on caspase-9. 
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In contrast to neutrophils, neither ketoconazole nor rutin could prevent acspase-9 
activation. 
 
Figure 7 Mitochondrial cytochrome c content in neutrophil granulocytes and lymphocytes. Cells were 
exposed for 24h to the compounds mentioned above at the concentrations given in the Figure labels. 
Some incubations contained also ketoconazole (1µM) or rutin (20µM) as indicated in the Figure labels. 
Cells treated with 0.1% DMSO were used as a negative (Ctrl) and cells treated with 1µM staurosporine 
as a positive control. The mitochondrial cytochrome c content was determined after cell 
permeabilization using flow cytometry as described in Methods. The results were normalized to 
control incubations (Ctrl) and are expressed as mean + SD of five independent experiments. (a) p<0.05 
incubations containing drugs alone versus respective control incubations (Ctrl); (b) p<0.05 incubations 
containing drugs and rutin or ketoconazole versus corresponding incubations containing drugs only. 
STS: staurosporine, Clp: clopidogrel, Tcp: ticlopidine, CCA: clopidogrel carboxylate. 
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Figure 8 Caspase 9 activity in neutrophil granulocytes and lymphocytes. The cells were treated for 24h 
with clopidogrel, ticlopidine or clopidogrel carboxylate at the concentrations given in the Figure 
labels. Some incubations contained also 1µM ketoconazole or 20µM rutin as indicated in the Figure 
labels. Cells treated with 0.1% DMSO were used as negative (Ctrl) and cells treated with 1µM 
staurosporine as a positive control. The fluorometric assay was performed as described in Methods. 
The results were normalized to control incubations (Ctrl) and are expressed as mean + SD of five 
independent experiments. (a) p<0.05 incubations containing drugs alone versus respective control 
incubations (Ctrl); (b) p<0.05 incubations containing drugs and rutin or ketoconazole versus 
corresponding incubations containing drugs only. STS: staurosporine, Clp: clopidogrel, Tcp: 
ticlopidine, CCA: clopidogrel carboxylate. 
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Our study showed that clopidogrel, the clopidogrel metabolite clopidogrel 
carboxylate as well as ticlopidine are toxic for neutrophil granulocytes in a 
concentration-dependent fashion. Cytotoxicity could almost completely be prevented 
by the addition of the MPO inhibitor rutin, but not by the CYP inhibitor 
ketoconazole. Clopidogrel, ticlopidine and clopidogrel carboxylate were also toxic 
for lymphocytes, but cytotoxicity for lymphocytes was less accentuated and could 
not be prevented by ketoconazole or rutin. 
Both thienopyridines studied, clopidogrel and ticlopidine, have to be activated 
before they can bind to the P2Y12-receptor and inhibit platelet aggregation. For 
clopidogrel, CYP1A2, 2B6, 2C9, 2C19 and 3A4 have been reported to be involved in 
the activation 31,39,40. For ticlopidine, the CYPs involved in the activation are less clear, 
but CYP2B6 and 2C19 appear also to be involved 30. Earlier studies assessing the 
expression of CYPs in human bone marrow have shown a high mRNA expression of 
CYP1A1, 1B1, 2C8, 2D6, 2E1, 2J2, 2R1, 2S1, 2U1 41, but not of CYPs involved in the 
activation of clopidogrel or ticlopidine. This is in line with the current study, 
showing a high expression of mainly CYP1B1 mRNA in granulocytes and 
lymphocytes, but not of CYPs involved in the activation of ticlopidine or clopidogrel. 
In line with mRNA expression, protein expression for CYP1A2, 2B6, 2C9, 2C19 and 
3A4 was not detectable in granulocytes or lymphocytes. Accordingly, metabolism or 
cytotoxicity of clopidogrel or ticlopidine associated with CYPs in granulocytes or 
lymphocytes was negligible. For neutrophil granulocytes this is shown in Fig. 2 and 
Fig. 3, demonstrating that cytotoxicity and degradation of clopidogrel and 
ticlopidine can be prevented almost completely by blocking MPO, but not by the 
CYP inhibitor ketoconazole. Furthermore, in lymphocytes, where MPO is lacking 
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(Fig. 1), degradation was minimal for ticlopidine and clopidogrel and not detectable 
for clopidogrel carboxylate (Fig. 3). 
As mentioned above and shown in Fig. 2, activation of clopidogrel or ticlopidine by 
MPO was also the cytotoxic principle of these compounds in neutrophil 
granulocytes. Accordingly, cytotoxicity could be prevented by the addition of rutin, 
but not of ketoconazole. Importantly, clopidogrel carboxylate could also be 
metabolized by MPO and the metabolites formed were toxic for neutrophil 
granulocytes. In line with these observations, in lymphocytes, where MPO is lacking 
(Fig. 1), cytotoxicity was less accentuated for clopidogrel or ticlopidine compared to 
neutrophils and could not be prevented by rutin or by ketoconazole. Similarly, 
clopidogrel carboxylate showed only a weak toxicity for lymphocytes which was not 
clearly concentration-dependent. This finding could be predicted from the 
observation that clopidogrel carboxylate was not metabolized by lymphocytes (Fig. 
4). These results are in line with our observations in human hematopoietic stem cells 
29. In human hematopoietic stem cells, both ticlopidine and clopidogrel were 
cytotoxic, cytotoxicity was increased by metabolites formed by MPO and clopidogrel 
carboxylate was only cytotoxic after metabolization by MPO. 
The current study was also designed to detect possible molecular mechanisms by 
which the investigated compounds exert cytotoxicity. The observed decrease in the 
mitochondrial membrane potential (Fig. 5) indicated that in particular metabolites 
formed by MPO from clopidogrel, ticlopidine or clopidogrel carboxylate impair 
mitochondrial function. The mitochondrial membrane potential can be decreased by 
various mechanisms, among them impairment of the mitochondrial electron 
transport chain 37,42. Impairment of the electron transport chain, particularly at 
complex I or III, can be associated with increased production of ROS 43,44. As shown 
in Fig. 6, cells exposed to clopidogrel or ticlopidine indeed showed increased ROS 
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accumulation, which could partially be blocked by rutin. Cellular accumulation of 
ROS can lead to mitochondrial membrane permeability transition, inducing 
mitochondrial swelling and eventually rupture of the outer mitochondrial membrane 
45,46. During this process, cytochrome c and other proteins located in the space 
between the inner and outer mitochondrial membrane are spilled into the cytoplasm, 
where they can become part of the apoptosome and initiate apoptosis 47,48. The results 
of the current study are compatible with this mechanism, showing a loss of 
mitochondrial cytochrome c (Fig. 7) and activation of caspase 9 (Fig. 8) by the 
compounds investigated. The role of metabolites formed by MPO is highlighted by 
the fact that rutin (but not ketoconazole) could prevent these processes almost 
completely. 
The median serum ticlopidine concentrations reached at steady state after the usual 
dose (250 mg every 12 h) were 990 µg/L or approximately 4 µM 49, a concentration 
close to the concentration where we started to observe cytotoxicity for neutrophil 
granulocytes. Since cytotoxicity of ticlopidine could almost completely be prevented 
by rutin, metabolites formed by MPO appear to be the myelotoxic principle at low 
ticlopidine concentrations as proposed by Liu and Uetrecht 28. The role of metabolites 
formed by MPO contained in neutrophil granulocytes concerning hematotoxicity of 
ticlopidine is also supported indirectly by the observation that lymphopenia has not 
been reported as an adverse reaction associated with ticlopidine. For clopidogrel, the 
serum concentration after the administration of a 600 mg loading dose is in the range 
of 38 µg/L or 0.1 µM 50. This concentration is much lower than the concentrations 
associated with cytotoxicity, indicating that non-metabolized clopidogrel is most 
probably not responsible for myelotoxicity. For clopidogrel carboxylate, serum 
concentrations in the range of 2780 µg/L or approximately 10 µM have been reported 
in patients treated with the usual daily dose of 75 mg 51. This concentration is close to 
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the concentration observed to be cytotoxic for neutrophil granulocytes and, to a 
lesser extent, also for lymphocytes. Considering clopidogrel, toxicity for neutrophil 
granulocytes can therefore be explained best by MPO-associated formation of toxic 
metabolites of clopidogrel carboxylate within neutrophil granulocytes. Such 
metabolites were not only toxic for mature neutrophil granulocytes, however, but 
also for hematopoietic progenitor cells 29. 
We conclude that metabolite formation by MPO is essential for the hematotoxicity of 
ticlopidine and clopidogrel. For clopidogrel, the hematotoxic metabolites are most 
probably formed from the inactive metabolite clopidogrel carboxylate, and for 
ticlopidine from the parent substance. These metabolites are mitochondrial toxins 
leading to cellular ROS accumulation and induction of apoptosis by the endogenous 
pathway. 
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We investigated the mechanism of cytotoxicity of ticlopidine, clopidogrel, 
clopidogrel carboxylate and prasugrel thiolactone on the promyelocytic leukemia cell 
line HL-60, highly passaged (spent) HL-60 cells stably transfected with cytochrome 
P450 (CYP) 3A4 (HL-60/CYP3A4). HL-60 cells had a high expression of 
myeloperoxidase (MPO) but no CYP3A4. In contrast, HL-60/3A4 cells had a high 
expression of CYP3A4 and no expression of MPO. All substances tested were 
cytotoxic for HL-60 cells, starting at 10µM. This toxicity could be prevented by the 
MPO inhibitor rutin, but not by the CYP inhibitor ketoconazole. All substances were 
metabolized by HL-60 cells, which could be blocked by rutin. Ticlopidine, 
clopidogrel and prasugrel thiolactone were also toxic for HL-60/CYP3A4 cells, again 
starting at 10µM. Cytotoxicity could be prevented by ketoconazole, but not by rutin. 
In contrast, clopidogrel carboxylate was not toxic for HL-60/CYP3A4 cells up to 
100µM. Ticlopidine, clopidogrel and prasugrel thiolactone were metabolized by HL-
60/CYP3A4 cells which could be blocked by ketoconazole. Metabolism of 
clopidogrel carboxylate by HL-60/CYP3A4 cells was negligible. Metabolites formed 
by MPO or by CYP3A4 decreased the mitochondrial membrane potential, increased 
ROS production, decreased the cellular GSH/GSSG ratio, were associated with a 
spill of cytochrome c into the cytosol and induced apoptosis. We conclude that all 
thienopyridines tested can form toxic metabolites following exposure to MPO, and, 
with the exception of clopidogrel carboxylate, also with CYP3A4. Cytotoxicity of the 
toxic metabolites formed can be explained by mitochondrial damage eventually 
leading to apoptosis. In vivo myelotoxicity of ticlopidine and clopidogrel can be 
explained by the formation of toxic metabolites by MPO within the bone marrow 
from the parent substance (ticlopidine) or from clopidogrel carboxylate (clopidogrel). 
Prasugrel is not myelotoxic in vivo, because the concentration of the metabolites 
reached in bone marrow is not high enough. 
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• MPO: myeloperoxidase 
• CYP: cytochrome P450 
• IMDM: Iscove’s modified Dulbecco’s medium 
• PBS: phosphate-buffered saline 
• FBS: fetal bovine serum 
• PI: propidium iodide 
• TMRE: tetramethylrhodamine ethyl ester 
• DCFH-DA: dichlorodihydrofluorescein-diacetate 
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The thienopyridines ticlopidine, clopidogrel and prasugrel are irreversible inhibitors 
of the ADP (P2Y12)-receptors on blood platelets 
1-3. By blocking platelet activation by 
ADP, they inhibit platelet aggregation. Accordingly, they are used in patients where 
platelet activation plays an important role, in particular in patients with 
cardiovascular disease including acute coronary syndrome 4,5, stroke 6,7 or peripheral 
arterial disease 6. 
All thienopyridines are prodrugs 8. All of them form a thiolactone derivative, which 
is then converted to the respective active metabolite. The formation of the thiolactone 
derivative is CYP-dependent for ticlopidine and clopidogrel 8 and is achieved by 
carboxylesterases for prasugrel 9. The formation of the active metabolite from the 
thiolactone derivative is also a CYP-dependent reaction. The most important CYPs 
involved in these reactions are CYP3A4, CYP2B6, CYP2C9 and CYP2C19 8,10. For 
prasugrel, the conversion of the thiolactone derivative (R-95913) to the active 
metabolite (R-138727) involves the formation of an S-oxide intermediate 11 achieved 
mainly by CYP3A4 and CYP2B6 10. The conversion of the S-oxide to the active 
metabolite R-138727 involves the formation of a glutathione conjugate 11. Similar to 
prasugrel, clopidogrel is also an ester. Approximately 85% of clopidogrel is 
hydrolyzed during the absorption process, leading to the formation of the inactive 
metabolite clopidogrel carboxylate 8. 
These agents are generally well tolerated. As expected, the most important adverse 
reaction associated with these drugs is bleeding. In large studies, major bleeding has 
been reported in 1 to 3.7% of the patients treated with clopidogrel 4-6 and in 2.4% of 
the patients treated with prasugrel 4. Also hepatotoxicity has been described for both 
ticlopidine 12-14 and clopidogrel 15-17. For prasugrel, patients with clinically relevant 
hepatotoxicity have so far not been reported. Myelotoxicity is an additional concern 
associated with both ticlopidine and clopidogrel. Both agents have been associated 
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with leucopenia and agranulocytosis as well as with aplastic anemia 18-20. Similar to 
hepatotoxicity, myelotoxicity has so far not been described for prasugrel. 
Interestingly, a patient has recently reported who developed severe neutropenia two 
weeks after starting treatment with clopidogrel. Since the patient had been treated 
with bare metal stents due to an acute coronary syndrome, he needed aggressive 
platelet aggregation inhibition for preventing stent thrombosis. Therefore, 
clopidogrel was replaced by prasugrel. During this treatment, the neutrophil count 
gradually normalized, demonstrating that prasugrel was not myelotoxic in this 
patient 21. 
In previous investigations, we have shown that both clopidogrel and ticlopidine 
show a concentration-dependent toxicity on human myeloid progenitor cells 22 and 
on mature human neutrophils and lymphocytes (Maseneni S et al. 2012;submitted). 
This toxicity was associated with both the respective parent compounds and with 
metabolites formed by myeloperoxidase (MPO) contained in neutrophil granulocytes 
22. Furthermore, metabolites formed by CYP3A4 can also contribute to cytotoxicity of 
these compounds, but most probably not in bone marrow 22. 
HL-60 cells are a human promyelocytic leukemia cell line 23 which contain MPO. 
After several passages, HL-60 cells lose the capability to express MPO and are called 
spent cells 24. Taking into account these properties, we reasoned that HL-60 cells 
could provide a suitable cell model to study the toxicity ticlopidine, clopidogrel, the 
clopidogrel metabolite clopidogrel carboxylate and prasugrel. Our aim was to study 
the molecular basis of the cytotoxicity of these compounds in HL-60 containing MPO 
and also in spent HL-60 cells stably transfected with human cytochrome P450 (CYP) 
3A4. Since the same cells were used, cytotoxicity associated with metabolites 
produced by MPO or CYP3A4 could be compared directly. 
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Clopidogrel hydrogen sulphate was extracted from commercially available tablets 
(brand name Plavix®) and clopidogrel carboxylate was obtained by alkaline 
hydrolysis of clopidogrel. These procedures were carried out by ReseaChem Life 
Sciences (Burgdorf, Switzerland). Both substances were >99% pure by NMR analysis. 
Ticlopidine was obtained from Sigma-Aldrich (Buchs, Switzerland). Prasugrel was 
obtained from Sirius Fine Chemicals SiChem GmbH (Bremen, Germany). Cell culture 
plates were purchased from BD Biosciences (Franklin Lakes, NJ, USA). The 
ToxiLight® assay kit was purchased from Lonza (Basel, Switzerland). The FuGENETM 
transfection kit was purchased from Promega (Dübendorf, Switzerland). All other 
chemicals and culture media used were purchased from Sigma (Buchs, Switzerland) 
and GIBCO (Lucerne, Switzerland), respectively. 
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The human promyelocytic leukemia cells (HL-60) were purchased from the 
American Type Culture Collection. HL-60 cells and HL-60 overexpressing CYP3A4 
(HL-60/CYP3A4 cells) were cultured in RPMI medium supplemented with 10% fetal 
bovine serum (FBS). Both cell lines were grown in a humidified incubator with 5% 
CO2 at 37oC. 
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The functional human CYP3A4 gene was excised from the pCR2.1-topo® vector 
(Zahno et .al 2010) and cloned into pCDNA 3.1 Hygro (+) plasmid (Invitrogen, 
Lucerne, Switzerland). Highly passaged HL-60 cells (Spent HL-60 cells, which have 
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lost the MPO gene) were transfected with the clone using FuGENETM transfection 
kit and allowed to grow in medium containing 150 µg/ml hygromycin B. 
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Cytotoxicity was determined either by the determination of the activity of adenylate 
kinase in the supernatant of cell incubations or by propidium iodide staining. 
Adenylate kinase activity was determined using the ToxiLight assay kit as described 
previously 25. Luminescence was measured using a Tecan Infinite pro 200 microplate 
reader (Tecan, Männedorf, Switzerland). For propidium iodide staining, cells were 
centrifuged at 350 g for 5 min after treatment with the compounds indicated in the 
Result section and washed with PBS before being exposed to propidium iodide (final 
concentration 5 µg/ml). Flow cytometry analysis was carried out with FACS 
CaliburTM using CellQuest Pro software (BD Bioscience, Allschwil, Switzerland). 
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Protein expression in HL-60 cells and HL-60/CYP3A4 cells was checked by Western 
blotting using a monoclonal antibody against human CYP3A4 (Epitomics, Danvers, 
USA) and a polyclonal antibody against human myeloperoxidase (Cell Signaling 
Technology, Allschwil, Switzerland). The cells were lysed on ice for 15 min with 200 
µl NET lysis buffer (50 mM NaCl, 5 mM EDTA, 0.05 M Tris-HCl pH 8.0, 1% NP-40 
and a protease inhibitor tablet from Roche, Basel, Switzerland). The samples were 
vortexed and centrifuged for 10 min at 4oC at 11,000 g. The supernatants were 
collected and the protein concentration determined using the Pierce BCA protein 
assay kit (Darmstadt, Germany). Proteins (20 µg) were separated by electrophoresis 
on a denaturating SDS polyacrylamide gel (4%) and were then transferred onto a 
nitrocellulose membrane (BioradTransBlot, Hercules, CA). The membranes were 
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blocked with blocking buffer (PBS/Tween 20 containing 5% milk solution) for 1h at 
room temperature and washed twice with PBS/Tween 20. The blocked membranes 
were then incubated overnight at 4oC with blocking buffer containing primary 
antibodies against MPO (1:1000) or CYP3A4 (1:1000). Horseradish peroxidase-labeled 
anti-rabbit or anti-mouse antibodies (Jackson laboratories Inc, Suffolk, UK) were 
used in combination with a chemiluminescent substrate (ECL, Amersham, UK) for 
visualization of the proteins. 
!"#"! $%&'()*)+&(),'- ,*- +.,/)0,123.4- +.,/)0,123.- +&25,67.&(34- ()+.,/)0)'3- &'0-
/2&8%123.-&'0-/2&8%123.-(9),.&+(,'3-:;<=>=?@A-
HL-60 cells and HL-60/CYP3A4 cells were incubated with clopidogrel, clopidogrel 
carboxylate, ticlopidine or prasugrel (10 and 100µM) at 37°C for different periods of 
time (0, 6, 12 and 24 h) in the presence or absence of the CYP3A4 inhibitor 
ketoconazole (1µM) 26 or the MPO inhibitor rutin (20µM) 27. The reactions were 
stopped by addition of 300µl of methanol. After centrifugation at 3000 g for 30min, 
the samples were analyzed with the LC-MS/MS method described previously 22, 
which could also be used to detect and quantify prasugrel and prasugrel thiolactone. 
The specific transitions of prasugrel and prasugrel thiolactone were 374!206 and 
332!109, respectively. 
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For the experiments, 2 x 105/ml HL-60 cells or HL-60/3A4 cells were seeded in 24-
well plates. Stock solutions of test compounds (clopidogrel, clopidogrel carboxylic 
acid, ticlopidine and prasugrel) were prepared in DMSO. The test compounds were 
added at a concentration of 1, 10 or 100 µM in presence or absence of the CYP3A4 
inhibitor ketoconazole (1µM) or the MPO inhibitor rutin (20µM). Control incubations 
contained DMSO; the DMSO concentration was identical in all incubations at 0.1%. 
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This DMSO concentration has been shown not to be cytotoxic 28. Staurosporine 1 µM 
(STS), diethyl-maleate 200 µM (DEM) or Triton X were used as positive controls. The 
drug treatment was performed for 24 h at 37oC and 5% CO2. 
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To detect the changes in mitochondrial membrane potential, tetramethylrhodamine 
ethyl ester (TMRE) was used. HL-60 cells or HL-60/CYP3A4 cells were incubated 
with drugs in the presence or absence of ketoconazole (1 µM) or rutin (20 µM) for 
24h. The cells were washed twice with PBS and incubated with 100 nM TMRE in PBS 
for 30min at room temperature. The fluorescence signal of the cationic dye was 
monitored by flow cytometry. 
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The cytochrome c content in the cells was analyzed using the method described by 
Waterhouse et al. 29 with some modifications. Briefly, after 24 h of treatment, the 
drug-treated cells were washed with PBS. The cells were then permeabilized on ice 
with 100 µl of digitonin (50 µg/ml in PBS containing 100 mM KCl) for 10 min. After 
permeabilization, the cells were fixed with paraformaldehyde (4% in PBS) at room 
temperature. After 30 min, the cells were washed twice with PBS and incubated for 1 
h in blocking buffer (PBS containing 3% BSA and 0.05% saponin). After incubation 
with a monoclonal anti-cytochrome c antibody (BD Pharmingen, Allschwil, 
Switzerland) diluted 1:500 in blocking buffer at 4°C overnight, the cells were washed 
twice with PBS and incubated with an Alexa Fluor®-labeled secondary antibody 
diluted 1:500 in blocking buffer (Invitrogen, Basel, Switzerland) for 1 h at room 
temperature. After this procedure, the cells were analyzed by flow cytometry. 
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Cellular ROS generation was measured using the 2’, 7’-dichlorodihydrofluorescein-
diacetate (DCFH-DA) assay 30. DCFH-DA is a membrane-permeable, non-fluorescent 
compound accumulating within cells as DCFH upon deacetylation by esterases. In 
presence of ROS, DCFH is oxidized to the fluorescent dichlorofluorescein (DCF). 
Cells were co-incubated with drugs and 25 µM DCFH-DA in the presence or absence 
of ketoconazole (1 µM) or rutin (20 µM). After 24 h of incubation, fluorescence was 
measured at an excitation wavelength of 485 nm and an emission wavelength of 535 
nm using a Tecan Infinite pro 200 microplate reader (Tecan, Männedorf, 
Switzerland). 
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Determination of glutathione (GSH) and oxidized glutathione (GSSG) was 
performed using the enzymatic recycling method of Rahman 31. Briefly, cells were 
incubated with the test compounds with and without inhibitors for 24h. Diethyl-
maleate (DEM), a glutathione depleting agent 32, served as a positive control. The 
cells were washed with PBS and 1ml of KPE buffer and sonicated for 30 sec. After 
centrifugation at 3000g for 4 min, the pellet was used for protein determination and 
the supernatant for the determination of total glutathione (GSH and GSSG). For the 
determination of total glutathione, a reaction mixture containing NADPH (0.8 mM), 
DTNB (1.6 mM) and glutathione reductase (4 U/ml) was added to samples or 
standards. The time-dependent formation of TNB was measured at 412 nm using the 
Tecan microplate reader. For the determination of GSSG, GSH was derivatized with 
2-vinylpyridine and GSSG was determined using the recycling assay described 
above. 
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An in situ apoptosis detection kit, Vybrant TM Apoptosis kit #2 (Invitrogen, Basel, 
Switzerland) was used to measure the apoptotic cells. After 24 h of incubation of the 
cells with test compounds with and without inhibitors, cells were washed with PBS 
and stained with Annexin V-AlexaFluor 488 and propidium iodide as described in 
the kit protocol. The samples were incubated for 15 minutes and analyzed by flow 
cytometry.  
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Data are presented as means ± SD of at least three independent experiments, except 
where indicated. Statistical analyses were performed using GraphPad Prism 5 
(GraphPad Software, La Jolla, CA, USA). Differences between groups (e.g. 
incubations containing drugs vs. control incubations) were tested by one-way 
ANOVA followed by Bonferroni’s post hoc test to localize significant results in the 
ANOVA. Differences between many groups at two levels were compared using two-
way analysis of variance (ANOVA) followed by the protected Dunnett’s post hoc test 
to localize significant results obtained in the ANOVA. A p-value <0.05 was 
considered as statistically significant. 
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The toxicity of the thienopyridines was assessed with two different cell types: non-
modified HL-60 cells, a human promyelocytic leukemia cell line containing 
myeloperoxidase (MPO), and HL-60 overexpressing human CYP3A4 (HL-
60/CYP3A4 cells). Western blot analysis revealed a high expression of MPO in HL-60 
cells, whereas CYP3A4 expression was barely detectable in this cell type (fig. 1). In 
contrast, in HL-60/CYP3A4 cells, CYP3A4 was highly expressed and expression of 
MPO was almost absent. 
 
Figure 1 Protein expression of myeloperoxidase (MPO) and CYP3A4 by Western blotting. Human 
liver microsomes (HLM) were used as a positive control for CYP3A4 enzyme expression and actin as a 
control to confirm equal loading. 
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HL-60 cells were incubated with different concentrations (1, 10 and 100 µM) of 
clopidogrel, ticlopidine, prasugrel, and clopidogrel carboxylate for 24 h and the 
cellular release of adenylate kinase was determined as a surrogate of cytotoxicity 
(Fig. 2). All drugs showed a dose-dependent cytotoxicity starting at 10 µM. 
An almost identical picture was obtained for HL-60/CYP3A4 cells (Fig. 2). For 
clopidogrel, ticlopidine and prasugrel, cytotoxicity was dose-dependent, starting at 
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10 µM. In contrast to HL-60 cells, clopidogrel carboxylate was not toxic for HL-
60/CYP3A4 cells up to 100 µM. Concerning prasugrel, it is important to realize that 
the parent compound was rapidly (<5 min) and completely hydrolyzed to prasugrel 
thiolactone (Fig. 3). The cells were therefore exposed to prasugrel thiolactone and not 
to prasugrel. 
 
Figure 2 Cytotoxicity of clopidogrel, ticlopidine, prasugrel thiolactone, and clopidogrel carboxylate 
for HL-60 and HL-60/CYP3A4 cells. Cells were exposed for 24h to the compounds mentioned above 
at the concentrations indicated in the Figure labels. Adenylate kinase was measured as a surrogate for 
cytotoxicity using the ToxiLight® assay. Control (Ctrl) incubations contained 0.1% DMSO and 
incubations containing 1µM staurosporine served as positive controls. The results are expressed as the 
means + SD of four independent experiments. a p<0.05 incubations containing drugs only (no 
inhibitor) versus respective control incubations (Ctrl). b p<0.05 incubations containing drugs and 
inhibitor (ketoconazole or rutin) versus respective incubations containing drugs only. STS: 
staurosporine, Clp: clopidogrel, Tcp: ticlopidine, CCA: clopidogrel carboxylate, Prs: prasugrel 
thiolactone. 
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To further characterize the two cell systems established, metabolism of the test 
compounds mentioned above was studied using LC-MS/MS. The cells were 
incubated for 24h with the test compounds in the presence or absence of the CYP3A4 
inhibitor ketoconazole 26 or the MPO inhibitor rutin 27. Two different initial 
concentrations were chosen, 10 µM (Fig. 3) and 100 µM (Fig. 4). As mentioned above 
prasugrel is rapidly and quantitatively hydrolyzed under the conditions used (data 
not shown); therefore prasugrel thiolactone is given in Fig. 3 and Fig. 4. As shown in 
fig. 3, in the presence of HL-60 cells, all compounds were degraded time-
dependently by 30 to 70% over 24 hours. Degradation could be blocked almost 
completely by rutin, but not by ketoconazole. Similar results were obtained with an 
initial concentration of 100 µM (Fig. 4). In the presence of HL-60/CYP3A4 cells, 
clopidogrel, ticlopidine and prasugrel thiolactone at an initial concentration of 10 µM 
were degraded by 50 to 95% over 24 hours (Fig. 3). The degradation could be blocked 
by ketoconazole, but not by rutin. In contrast to HL-60 cells, clopidogrel carboxylate 
was not degraded by HL-60/CYP3A4 cells. Similar results were obtained for an 
initial concentration of 100 µM (Fig. 4). 
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Figure 3 Metabolism of clopidogrel, ticlopidine, prasugrel thiolactone and clopidogrel carboxylate by 
HL-60 cells (Fig.3A-D) or HL-60/CYP3A4 cells (Fig. 3E-G). The test compounds were added to the 
cells at an initial concentration of 10µM and the concentration of the compounds was determined for 
24 hours. Some incubations contained also the myeloperoxidase inhibitor rutin (20µM) or the CYP3A4 
inhibitor ketoconazole (1µM) as indicated in the Figure label. Data are expressed as the percentage of 
parent drug remaining during 24h of incubation. The results are the means + SD of three independent 
determinations. a p<0.05 versus respective incubations at time 0 min; b p<0.05 incubations containing 
drug with 20µM rutin or ketoconazole 1µM versus respective incubations containing drug only. 
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Figure 4 Metabolism of clopidogrel, ticlopidine, prasugrel thiolactone and clopidogrel carboxylate by 
HL-60 cells (Fig.3A-D) or HL-60/CYP3A4 cells (Fig. 3E-G). The test compounds were added to the 
cells at an initial concentration of 100µM and the concentration of the compounds was determined for 
24 hours. Some incubations contained also the myeloperoxidase inhibitor rutin (20µM) or the CYP3A4 
inhibitor ketoconazole (1µM) as indicated in the Figure label. Data are expressed as the percentage of 
parent drug remaining during 24h of incubation. The results are the means + SD of three independent 
determinations. a p<0.05 versus respective incubations at time 0 min; b p<0.05 incubations containing 
drug with 20µM rutin or ketoconazole 1µM versus respective incubations containing drug only. 
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Cytotoxicity was assessed using PI staining and subsequent FACS analysis (Fig. 5). 
For HL-60 cells exposed for 24h, clopidogrel, ticlopidine, prasugrel thiolactone and 
clopidogrel carboxylate showed a concentration-dependent toxicity. Cytotoxicity 
could at least partially be prevented by the MPO inhibitor rutin 27. In comparison, for 
HL-60/CYP3A4 cells only clopidogrel, ticlopidine and prasugrel thiolactone were 
cytotoxic in a concentration-dependent fashion, whereas clopidogrel carboxylate was 
not toxic. Cytotoxicity of clopidogrel, ticlopidine and prasugrel could be prevented 
by the CYP3A4 inhibitor ketoconazole 
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Since mitochondria are important mediators of cell death, we investigated the effect 
of the thienopyridine compounds studied on !m. As shown in Fig. 6, in HL-60 cells, 
all compounds tested were associated with a concentration-dependent decrease in 
!m. With the exception of 100 µM prasugrel thioalctone, where rutin was only 
partially preventive, rutin was able to prevent this decrease completely. A similar 
picture could be observed in HL-60/CYP3A4 cells, where ketoconazole could 
prevent almost completely the drop in !m. In contrast to HL-60 cells, clopidogrel 
carboxylate was not reducing !m in HL-60/CYP3A4 cells. 
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Figure 5 Effect of enzyme inhibitors on the cytotoxicity of clopidogrel, ticlopidine, prasugrel 
thiolactone, and clopidogrel carboxylate for HL-60 and HL-60/3A4 cells. Cells were exposed for 24h 
to the compounds mentioned above at the concentrations indicated in the Figure labels. Some 
incubations contained also 1µM ketoconazole (CYP3A4 inhibitor) or 20µM rutin (MPO inhibitor) as 
indicated in the figure labels. Cytotoxicity was measured using propidium iodine staining. Control 
incubations (Ctrl) contained 0.1% DMSO (Ctrl). Positive control incubations contained 1µM 
staurosporine. The results were normalized to control incubations (Ctrl) and are expressed as the 
means + SD of five independent experiments. a p<0.05 incubations containing drugs only (no enzyme 
inhibitor) versus respective control incubations (Ctrl); b p<0.05 incubations containing drugs and rutin 
or ketoconazole versus corresponding incubations containing drugs only. STS: staurosporine, Clp: 
clopidogrel, Tcp: ticlopidine, CCA: clopidogrel carboxylate, Prs: prasugrel thiolactone. 
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Figure 6 Effect of clopidogrel, ticlopidine, prasugrel thiolactone, and clopidogrel carboxylate on the 
mitochondrial membrane potential in HL-60 and HL-60/CYP3A4 cells. Cells were incubated for 24 h 
with different concentrations of the compounds mentioned above as indicated in the Figure labels. 
Some incubations contained ketoconazole (1µM) or rutin (20µM) as indicated. The decrease of 
mitochondrial membrane potential was measured using the fluorescent dye TMRE. The results were 
normalized to control incubations containing 0.1% DMSO (Ctrl). Incubations containing 1µM 
staurosporine served as positive controls. Results are presented as the mean + SD of three 
independent experiments. a p<0.05 incubations containing drugs alone (no enzyme inhibitors) versus 
respective control incubations (Ctrl); b p<0.05 Incubations containing drugs and rutin or ketoconazole 
versus corresponding incubations containing drugs only. STS: staurosporine, Clp: clopidogrel, Tcp: 
ticlopidine, CCA: clopidogrel carboxylate, Prs: prasugrel thiolactone. 
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Mitochondrial dysfunction can be associated with increased ROS production 30. As 
shown in supplementary fig. 3, the cellular ROS content of HL-60 cells increased in 
concentration-dependent fashion in the presence of clopidogrel, ticlopidine, 
prasugrel thiolactone and clopidogrel carboxylate. Accumulation of ROS could be 
prevented by the addition of rutin, indicating that metabolites formed by MPO were 
responsible for this finding. Similarly, the cellular ROS content of HL-60/CYP3A4 
cells increased in a concentration-dependent fashion in the presence of clopidogrel, 
ticlopidine or prasugrel thiolactone, but not in the presence of clopidogrel 
carboxylate. The CYP3A4 inhibitor ketoconazole prevented ROS accumulation at 
least partially. 
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The GSH/GSSG ratio can be regarded as a marker of oxidative stress, since GSH is 
oxidized to GSSG during the degradation of ROS such as hydrogen peroxide. As 
shown in fig. 5, all thienopyridines studied decreased the GSH/GSSG ratio in HL-60 
cells. This decrease was concentration-dependent and could be prevented by the 
addition of rutin. In HL-60/CYP3A4 cells, a similar decrease was observed for 
clopidogrel, ticlopidine and prasugrel thiolactone, but not for clopidogrel 
carboxylate. This decrease could at least partially be prevented by the addition of the 
CYP3A4 inhibitor ketoconazole. 
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Figure 7 ROS accumulation in HL-60 and HL-60/CYP3A4 cells in the presence of clopidogrel, 
ticlopidine, prasugrel thiolactone or clopidogrel carboxylate. Cells were exposed for 24h to the above-
mentioned compounds and to enzyme inhibitors as indicated in the figure labels. Cellular levels of 
ROS were measured using 2’, 7’-dichlorodihydrofluorescein-diacetate. Incubations containing 0.1% 
DMSO were used as control (Ctrl). Incubations with depletion of the cellular glutathione by 200µM 
diethylmaleate were used as positive controls (DEM). The results were normalized to control 
incubations (Ctrl) and are expressed as mean + SD of three independent experiments. a p<0.05 
incubations containing drugs alone (no enzyme inhibitors) versus respective control incubations 
(Ctrl); b p<0.05 incubations containing drugs and rutin or ketoconazole versus corresponding 
incubations containing drugs only. STS: staurosporine, Clp: clopidogrel, Tcp: ticlopidine, CCA: 
clopidogrel carboxylate, Prs: prasugrel thiolactone. 
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Figure 8 Effect of clopidogrel, ticlopidine, prasugrel thiolactone, and clopidogrel carboxylate on the 
GSH/GSSG ratio in HL-60 and HL-60/CYP3A4 cells. Cells were incubated for 24h with different 
concentrations (indicated in the figure labels) of the compounds mentioned above. Some incubations 
contained ketoconazole (1µM) or rutin (20µM) as indicated in Figure labels. Incubations containing 
0.1% DMSO served as controls (Ctrl).  Incubations containing the GSH depleting agent diethylmaleate 
(200 µM) served as a second control (DEM). The results were normalized to control incubations (Ctrl) 
and are expressed as mean + SD of three independent experiments. a p<0.05 incubations containing 
drugs alone (no enzyme inhibitors) versus respective control incubations (Ctrl); b p<0.05 incubations 
containing drugs and rutin or ketoconazole versus corresponding incubations containing drugs only. 
STS: staurosporine, Clp: clopidogrel, Tcp: ticlopidine, CCA: clopidogrel carboxylate, Prs: prasugrel 
thiolactone. 
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Increased mitochondrial ROS production can lead to the opening of the 
mitochondrial permeability transition pore with subsequent release of cytochrome c 
into the cytosol and initiation of apoptosis 30. In HL-60 cells, all thienopyridines 
tested were associated with a concentration-dependent in mitochondrial cytochrome 
c (Fig. 6). This decrease could be prevented by the addition of rutin. In comparison, 
in HL-60/CYP3A4 cells, such a decrease could only be observed for clopidogrel, 
ticlopidine and prasugrel thiolactone, but not for clopidogrel carboxylate. The 
addition of ketoconazole could partially prevent this decrease. 
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Since the release of cytochrome c is associated with apoptosis, we determined the 
proportion of apoptotic cells using annexin V/PI staining. Parallel to the findings for 
cytochrome c release presented above, all thienopyridines induced apoptosis in a 
concentration-dependent fashion in HL-60 cells (Fig. 7). As expected, the addition of 
rutin could prevent apoptosis. In comparison, only clopidogrel, ticlopidine and 
prasugrel thioalctone, but not clopidogrel carboxylate, induced apoptosis in HL-
60/CYP3A4 cells. Similar to the observation regarding cytochrome c release, 
ketoconazole could partially prevent induction of apoptosis. 
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Figure 9 Effect of clopidogrel, ticlopidine, prasugrel thiolactone and clopidogrel carboxylate on the 
mitochondrial cytochrome c content in HL-60 and HL-60/CYP3A4 cells. Cells were incubated with the 
test compounds for 24h at the concentrations given in the Figure labels. Some incubations contained 
also ketoconazole or rutin as indicated in the Figure labels. Control incubations contained 0.1% DMSO 
(Ctrl). Positive control incubations contained 1µM staurosporine. The mitochondrial cytochrome c 
content was determined by flow cytometry after cell permeabilization as described in Methods. The 
results were normalized to control incubations (Ctrl) and are expressed as mean + SD of four 
independent experiments. a p<0.05 incubations containing drugs alone (no enzyme inhibitors) versus 
respective control incubations (Ctrl); b p<0.05 incubations containing drugs and rutin or ketoconazole 
versus corresponding incubations containing drugs only. STS: staurosporine, Clp: clopidogrel, Tcp: 
ticlopidine, CCA: clopidogrel carboxylate, Prs: prasugrel thiolactone. 
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Figure 10 Induction of apoptosis in HL-60 and HL-60/CYP3A4 cells by clopidogrel, ticlopidine, 
prasugrel thiolactone and clopidogrel carboxylate. Cells were treated with the compounds mentioned 
above for 24h at the concentrations indicated in the figure labels. Apoptosis was determined by 
staining with annexin V/propidium iodine followed by flow cytometry. Control incubations 
contained 0.1% DMSO (Ctrl). Positive control incubations contained 1µM staurosporine. The results 
were normalized to control incubations (Ctrl) and are expressed as mean + SD of four independent 
experiments. a p<0.05 incubations containing drugs alone (no enzyme inhibitors) versus respective 
control incubations (Ctrl); b p<0.05 incubations containing drugs and rutin or ketoconazole versus 
corresponding incubations containing drugs only. STS: staurosporine, Clp: clopidogrel, Tcp: 
ticlopidine, CCA: clopidogrel carboxylate, Prs: prasugrel thiolactone. 
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Our study shows that all compounds tested were metabolized by MPO and were 
toxic for HL-60 cells. Cytotoxicity was clearly concentration-dependent and started at 
10 µM. Prevention of the cytotoxicity by rutin confirmed that the toxicity was 
associated with metabolites formed by MPO. With the exception of clopidogrel 
carboxylate, all compounds tested were also metabolized by CYP3A4. They showed 
a concentration-dependent toxicity on HL-60/CYP3A4 cells which could be 
prevented by ketoconazole. Clopidogrel carboxylate was not cytotoxic in this cell 
model. 
Regarding the role of MPO in metabolism and cytotoxicity of clopidogrel, 
clopidogrel carboxylate and ticlopidine, the current study confirms our observations 
in myeloid progenitor cells 22 and in mature neutrophil granulocytes and 
lymphocytes (Maseneni S. et al. 2012;submitted). As described by Liu and Uetrecht in 
detail for ticlopidine 33, these compounds are metabolized by MPO and the 
metabolites formed by MPO increase their cytotoxicity. Importantly, this is also true 
for the inactive clopidogrel metabolite clopidogrel carboxylate, which may explain 
myelotoxicity of clopidogrel 22. 
Our study shows that also prasugrel thiolactone is metabolized by MPO (Fig. 2 and 
supplementary Fig. 2) and that the metabolites produced are toxic for HL-60 cells 
(Fig. 3). In contrast to ticlopidine and clopidogrel, myelotoxicity has so far not been 
described for prasugrel. After ingestion of 15 mg prasugrel (close to the normal 
maintenance dose of 10 mg per day), the Cmax of prasugrel thiolactone (R-95913) is in 
the range of 70 µg/L, corresponding to approximately 0.2 µM 34. Prasugrel 
thiolactone has a half-life in the range of 4 h and can therefore be expected to reach 
the bone marrow. In the current study, prasugrel thiolactone was not toxic at 1 µM 
and started to be toxic at 10 µM. Our data are therefore in agreement with the clinical 
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observation that prasugrel is not myelotoxic; the concentrations reached in the bone 
marrow are too low, even after having been metabolized by MPO. 
In addition to MPO, ticlopidine, clopidogrel and prasugrel thiolactone were also 
metabolized by CYP3A4. This was not the case for clopidogrel carboxylate, a finding, 
which is in agreement with previous results obtained human recombinant CYP3A4 
(Maseneni et al., 2012). The finding that clopidogrel carboxylate cannot be 
metabolized by CYP3A4 can be explained by inability of the polar carboxyl moiety to 
access the active site of CYP3A4 (Zahno et al., 2010). Studies from our laboratory 22 
and from others 35,36 have shown that expression of the CYPs, which are important for 
the metabolism and activation of the thienopyridines, among them CYP3A4, 
CYP2B6, CYP2C9 and CYP2C19, is virtually absent in bone marrow. Potentially toxic 
metabolites formed from thienopyridines formed by CYPs have therefore to be 
transported (mainly from liver) to the bone marrow to exert their toxicity. This may 
be possible for ticlopidine, but not for clopidogrel, for which the concentrations 
reached are not high enough and the intermediates formed are to reactive 22. 
Assuming that CYP3A4 converted prasugrel thiolactone into the active metabolite R-
138727, the same conclusion can be drawn also for prasugrel. After oral ingestion of 
15 mg prasugrel, the plasma Cmax of R-138727 reached 80 µg/ml, corresponding to 
approximately 0.2 µM. The half-life of R-138727 is also in the range of 4 h, this 
metabolite reaches therefore the bone marrow. In the presence of CYP3A4, prasugrel 
thiolactone was not toxic at 1 µM and started to be toxic at 10 µM. Again, the 
concentration reached in vivo is too low to be myelotoxic, again explaining the 
absence of myelotoxicity for prasugrel. On the other hand, the liver may be exposed 
to higher concentrations of toxic metabolites produced by CYPs, which may explain 
the hepatotoxicity associated with ticlopidine and clopidogrel 12-17. This hypothesis is 
currently being investigated in human liver cell models. 
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The mechanism of cytotoxicity is compatible with a primary effect on mitochondria 
for both MPO- and CYP3A4-associated metabolites, as suggested by the decrease in 
the mitochondrial membrane potential. This finding is in agreement with our 
previous studies 22 (Maseneni et al. 2012; submitted). Increased production of ROS, 
cytochrome c spillage into the cytosol and apoptosis are consequences of the initial 
mitochondrial damage 29,30. Interestingly, both MPO- and CYP3A4-associated 
metabolite formations were associated with an decrease in the cellular GSH/GSSG 
ratio. This can be explained by the formation and detoxification of ROS, but may also 
be, in the case of CYP3A4, a consequence of the formation of the respective active 
metabolites, which is dependent on GSH 11. 
In conclusion, myelotoxicity of ticlopidine and clopidogrel is mainly explained by the 
formation of toxic metabolites by MPO within the bone marrow from the parent 
compound (ticlopidine) or from clopidogrel carboxylate (clopidogrel). Prasugrel is 
not myelotoxic, because the concentration of the metabolites reached in bone marrow 
is not high enough. Cytotoxicity of toxic metabolites formed by MPO or CYP3A4 can 
be explained by mitochondrial damage eventually leading to apoptosis. 
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Thienopyridines are prodrugs that requires hepatic conversion mainly by 
cytochrome P450 enzymes to an active metabolite in order to exert their antiplatelet 
effect.24,113,114 Thienopyridine therapy although increased inhibition of P2Y12 receptor 
and improved platelet function efficacy when compared to aspirin, adverse drug 
reaction was also increased. Besides hepatotoxicity 84,87, also bone marrow toxicity 
78,106,115-117 may limit their use. The mechanisms associated with myelotoxicity of 
thienopyridines are currently unclear. Therefore this thesis investigates the 
mechanism by which thienopyridines induce myelotoxicity. 
The first part of this thesis was designed to study an in vitro model of cytotoxicity of 
clopidogrel, ticlopidine and clopidogrel carboxylate in human hematopoietic 
progenitor cells. Using LC-MS, CYP3A4 supersomes and human neutrophils derived 
from peripheral blood were utilised to assess the metabolism of clopidogrel, 
ticlopidine and clopidogrel carboxylate in presence of CYP3A4 inhibitor 
(ketoconazole) or MPO inhibitor (rutin). In agreement with other findings 23,111,112, 
clopidogrel and ticlopidine was readily metabolised by CYP3A4 supersomes. 
Clopidogrel carboxylate, the major inactive metabolite of clopidogrel produced by 
hydrolysis with esterases 23 was not metabolized by CYP3A4.  In contrast, human 
neutrophils metabolized ticlopidine, clopidogrel and clopidogrel carboxylate 
significantly. The results revealed that preincubation of clopidogrel with CYP3A4 
were associated with increased toxicity, suggesting that the toxic metabolite could be 
important for myelotoxicity. As the CYP-mediated metabolites are not produced in 
bonemarrow118,119, they would have to be transported into bone marrow to exert 
myelotoxicity. Since the plasma concentration of active metabolite of clopidogrel was 
very low 113, the possibility that MPO and or CYP3A4 associated with active 
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metabolite of clopidogrel appears therefore to be unlikely. Most likely the 
myelotoxicity of clopidogrel is likely to be MPO-associated formation of toxic 
metabolites form clopidogrel carboxylate. Similar to clopidogrel, ticlopidine was also 
metabolized by CYP3A4.120 Due to their high plasma concentration, it appears that 
the metabolites of ticlopidine could reach bone marrow to contribute to the 
myelotoxicity of ticlopidine.121,122 for ticlopidine, the myelotoxicity could be explained 
by ticlopidine itself and MPO-associated formation of metabolites. 
The second part of the thesis investigates the molecular mechanism of cell death due 
to clopidogrel, ticlopidine and clopidogrel carboxylate in human neutrophils and 
lymphocytes. The metabolism or cytotoxicity of clopidogrel or ticlopidine associated 
with CYPs in neutrophils or lymphocytes are negligible due to low expression of 
CYPs.118 Our results showed metabolism or cytotoxicity of clopidogrel, ticlopidine 
and clopidogrel carboxylate for neutrophils. This metabolism and cytotoxicity was 
inhibited by MPO inhibitor, rutin but not by the CYP3A4 inhibitor, ketoconazole. 
Further more in lymphocytes, where MPO is lacking, metabolism of clopidogrel and 
ticlopidine were minimum and not detectable in clopidogrel carboxylate. There 
results support our previous findings in haematopoietic progenitor cells. Further 
more, molecular mechanism by which compounds exert toxicity was studies. The 
results revealed a decrease in mitochondrial membrane indicating by metabolites 
formed by MPO from clopidogrel, ticlopidine and clopidogrel carboxylate could 
impair mitochondrial function. The impairment of electron transport could be 
associated with in cellular accumulation of ROS.123,124 An increase in ROS production 
was observed in metabolites of clopidogrel, ticlopidine and clopidogrel carboxylate 
formed by MPO, which could be completely inhibited by blocker of MPO and not by 
blocker of CYP3A4. Increase in ROS production can eventually lead to release or 
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mitochondrial proteins (cytochrome c) and triggers caspases to induce apoptosis 125-
127, which is compatible with this thesis results by compounds investigated. The 
metabolites formed by MPO of clopidogrel, ticlopidine and clopidogrel carboxylate 
are important for hematotoxicity. Since the plasma concentration of clopidogrel in 
vivo is very low, the hematotoxicity associated with clopidogrel is mainly due to the 
inactive metabolite of clopidogrel. In ticlopidine, the toxicity could be explained by 
ticlopidine itself and the metabolites formed by MPO. These metabolites formed are 
mitochondrial toxins leading to accumulation of the cellular ROS triggering to the 
induction of apoptosis. 
The final part of thesis specifically investigates the myelotoxicity of clopidogrel, 
ticlopidine, prasugrel thiolactone, and clopidogrel carboxylate in both CYP3A4 (HL-
60/CYP3A4 cells) and MPO (HL-60 cells) cell models. HL-60 cells had high amount 
of MPO expression but no CYP3A4. In contrast HL-60/CYP3A4 cells had high 
expression of CYP3A4 but no MPO. HL-60 cells showed degradation of clopidogrel, 
ticlopidine, prasugrel thiolactone, and clopidogrel carboxylate, supporting the data 
of Liu and Uetrecht 111. The degradation of the compounds in HL-60 cells was 
associated with cytotoxicity that could be inhibited by MPO blocker (rutin) and not 
by CYP3A4 inhibitor (ketoconazole), indicating the role of MPO metabolism and 
supporting our previous data with myeloid progenitor cells and granulocytes. In 
contrast, HL-60/CYP3A4 cells metabolize clopidogrel, ticlopidine and prasugrel 
thiolactone but not clopidogrel carboxylate. The toxicity of HL-60/CYP3A4 
associated with clopidogrel, ticlopidine and prasugrel thiolactone were inhibited by 
ketoconazole completely. Clopidogrel carboxylate showed no toxicity in HL-
60/CYP3A4, suggesting the role of CYP3A4 metabolism of thienopyridines. The 
mechanism of cytotoxicity is compatible with mitochondrial dependent pathway 
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leading to apoptosis in both the cell models. An oxidative stress reaction (as 
evidenced by decrease in glutathione levels) promoted elevated ROS level, damaged 
mitochondrial, decrease of cellular cytochrome c content, and triggering of caspases 
for apoptosis. 
In Summary, the myelotoxicity of clopidogrel and ticlopidine is mainly by the 
formation of toxic metabolites by MPO within the bone marrow from the parent 
compound (ticlopidine) or from clopidogrel carboxylate (clopidogrel). Prasugrel is 
not myelotoxic, because the concentration of the metabolites reached in bone marrow 
is not high enough. Cytotoxicity of toxic metabolites formed by MPO or CYP3A4 can 
be explained by mitochondrial damage eventually leading to apoptosis. 
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